Arcutis (ARQT) Q3 2023: Zoryve Prescribers Climb to 9,000 as Market Access Drives 70% Revenue Growth
Arcutis delivered a pivotal quarter, expanding Zoryve’s prescriber base to 9,000 and unlocking broad payer access, fueling 70% sequential revenue growth. The company’s commercial execution and formulary wins set the stage for a tenfold addressable market expansion in 2024 with upcoming launches in seborrheic and atopic dermatitis. Investors should watch for accelerating conversion from topical steroids and the impact of Medicare and Medicaid penetration on both growth and gross-to-net.
Summary
- Prescriber Base Expansion: Zoryve’s unique positioning and payer wins drove 9,000 prescribers, deepening market penetration.
- Market Access Momentum: Two of three major PBMs will cover Zoryve foam at launch, supporting rapid uptake in new indications.
- 2024 Growth Catalyst: Upcoming launches in seborrheic and atopic dermatitis unlock a tenfold increase in U.S. patient opportunity.
Business Overview
Arcutis Biotherapeutics is a commercial-stage biopharmaceutical company focused on developing and marketing innovative topical treatments for immune-mediated dermatological diseases. The company’s core revenue driver is Zoryve, a topical phosphodiesterase-4 (PDE4) inhibitor, currently approved for plaque psoriasis and expected to expand into seborrheic dermatitis and atopic dermatitis. Its business model relies on prescription drug sales, supported by payer access, prescriber adoption, and expansion into broader patient segments through new indications and label expansions.
Performance Analysis
Arcutis posted net product revenue of $8.1 million for the quarter, marking a 70% sequential increase driven by both prescription demand and substantial improvements in gross-to-net realization. The number of unique Zoryve prescribers grew to 9,000, with over 110,000 prescriptions written since launch, reflecting growing clinical adoption and successful commercial execution. The company’s ability to secure coverage with all three major pharmacy benefit managers (PBMs) within the first year has been central to this acceleration, with over 130 million commercial lives covered and 90% of those without prior authorization requirements.
Prescription refill rates also climbed, up 50% quarter-over-quarter, signaling strong patient retention and satisfaction. The recent expansion of the sales force by 15%, targeted at high-volume geographies, further amplified Zoryve’s reach. Gross-to-net improvements were attributed to increased payer coverage, especially the CVS PBM win, and are expected to continue as the company deepens collaborations with contracted pharmacy partners and expands into Medicare and Medicaid in early 2024.
- Access-Driven Uptake: Broad commercial coverage and payer wins directly translated into higher prescription volumes and improved financial realization.
- Refill and Adherence Tailwind: 50% quarter-over-quarter growth in refills underpins sustainable demand and long-term patient engagement.
- Pipeline Leverage: Upcoming launches in new indications are positioned to benefit from established payer and prescriber infrastructure.
Arcutis also strengthened its balance sheet with a $100 million capital raise and revised its debt covenants for greater operational flexibility, extending its cash runway into 2025 and positioning the company to capitalize on its expanding market opportunity.
Executive Commentary
"We now have over 110,000 prescriptions and about 9,000 unique prescribers launched to date as our product delivers positive clinical experience for healthcare providers and their patients. This positive tailwind sets us up to launch our future topical reflumilast formulations as well from a position of strength."
Frank Watanabe, President and CEO
"Zoryve’s differentiated pricing and access strategy continues to resonate with payers, with over 130 million commercial lines covered, 90% without a prior authorization. We anticipate further improvements in Zoryve commercial coverage as we go into 2024, as well as accelerated commercial coverage for the foam at launch."
Todd Edwards, Chief Commercial Officer
Strategic Positioning
1. Market Access as a Growth Engine
Arcutis’s payer strategy is driving rapid adoption, with all three major PBMs now covering Zoryve and two set to cover the foam formulation at launch. This broad coverage underpins both current momentum and the scalability of future indications, allowing the company to bypass the typical slow ramp seen with new dermatology launches.
2. Indication Expansion and TAM Multiplication
The company is poised to expand Zoryve’s addressable market from 1.3 million psoriasis patients to over 13 million across seborrheic and atopic dermatitis, with further upside from Medicare and Medicaid populations. Regulatory milestones—including pediatric label expansion and positive long-term data— support this growth trajectory and position Arcutis to capture share from entrenched generic standards of care.
3. Commercial Execution and Sales Force Optimization
A 15% increase in field force, targeted at high-volume geographies, is designed to deepen prescriber engagement and drive adoption in both current and future indications. The company’s focus on prescription depth (increasing scripts per prescriber) and breadth (adding new prescribers) is supported by targeted direct-to-consumer campaigns and expanded patient support initiatives.
4. Capital and Operational Discipline
Recent capital raises, out-licensing deals, and restructured debt covenants have fortified the balance sheet, providing a cash runway into 2025. Operationally, Arcutis has realigned its organization, merging technical and product development functions and streamlining R&D spend to focus on near-term commercial opportunities.
5. Partnership Strategy for Non-Dermatology Channels
With roughly half the atopic and seborrheic dermatitis markets managed outside dermatology, Arcutis is actively pursuing partnerships to reach primary care and pediatric prescribers, aiming to unlock the full commercial potential without diluting commercial focus or inflating fixed costs.
Key Considerations
This quarter marks a critical inflection for Arcutis as it transitions from single-indication commercial execution to multi-indication scale-up. The company’s strategy is built on leveraging payer access, prescriber engagement, and operational flexibility to drive both top-line growth and margin improvement.
Key Considerations:
- Conversion Dynamics: Management expects conversion from topical steroids to non-steroidal therapies to follow historical analogs, with current penetration at 5% after one year and a long-term target of 50%.
- Medicare and Medicaid Penetration: Zoryve’s pricing below the CMS specialty threshold positions it for broad access and minimal gross-to-net dilution as government coverage ramps in 2024.
- Foam Launch Execution: The seborrheic dermatitis foam launch will benefit from immediate coverage at two major PBMs, supporting faster uptake than typical new assets.
- Prescriber Base Expansion: With 9,000 of 13,000 target dermatology prescribers writing scripts, there is ample room for both breadth and depth growth, especially as new indications launch.
- Operational Leverage: Streamlined R&D and SG&A investment are calibrated to support near-term launches without overextending the cost base.
Risks
Key risks include the pace of prescriber conversion from topical steroids, potential delays or setbacks in regulatory approvals for new indications, and the challenge of efficiently penetrating primary care and pediatric markets without a dedicated sales force. Gross-to-net improvements are contingent on continued payer wins and government access, while competitive dynamics in dermatology could intensify if new branded entrants emerge or generic alternatives see renewed uptake.
Forward Outlook
For Q4 2023, Arcutis expects:
- Further Zoryve demand growth and incremental gross-to-net improvement versus Q3
- Seborrheic dermatitis foam launch in mid to late January 2024, with immediate coverage at two major PBMs
For full-year 2024, management targets:
- Significant revenue acceleration driven by new indication launches and expanded payer access
- R&D expense decline versus 2023, with continued SG&A investment to support commercial launches
Management emphasized the importance of Medicare and Medicaid access, successful foam launch execution, and the pursuit of a primary care partnership as key drivers for sustained growth in 2024 and beyond.
- Primary care partnership discussions are ongoing, with a goal to have an agreement in place around atopic dermatitis approval
- Gross-to-net expected to approach target levels for psoriasis by the second half of 2024
Takeaways
Arcutis’s commercial and access execution has created a strong foundation for multi-indication growth. The company’s ability to convert prescribers, secure broad payer coverage, and scale efficiently will be critical as it enters larger, less-penetrated markets.
- Access and Payer Wins: Broad PBM coverage and a favorable pricing strategy have accelerated Zoryve’s adoption and set up the foam launch for rapid uptake.
- Execution on Indication Expansion: Regulatory progress and clinical data support a tenfold TAM increase, with operational and commercial infrastructure poised to scale.
- 2024 Watchpoints: Investors should monitor the pace of government access ramp, prescriber base deepening, and the impact of primary care partnerships on long-term adoption curves.
Conclusion
Arcutis has moved decisively from single-indication launch to a multi-indication growth platform, leveraging payer access and commercial execution to unlock significant market opportunity. Sustained momentum in prescriber conversion and successful execution in new indications will determine the company’s ability to scale revenue and deliver long-term value.
Industry Read-Through
Arcutis’s experience reinforces the critical importance of payer access and targeted commercial execution in specialty dermatology. The rapid PBM wins and focus on gross-to-net optimization highlight the leverage available to innovative entrants that can differentiate clinically and price strategically. The company’s approach to government access and partnership for primary care channels offers a roadmap for other biopharma companies seeking to maximize reach without overextending sales infrastructure. As more dermatology players look to expand beyond specialist prescribers, the need for partnership models and payer-aligned pricing will likely define future winners in this space.